← Back to Search

Gastrograﬁn for Small Bowel Obstruction

Phase 2 & 3

Waitlist Available

Research Sponsored by Lawson Health Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, up to 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if Gastrografin, a special liquid that helps clear intestinal blockages, can reduce the need for surgery in children with small bowel obstruction. It works by drawing water into the intestines to help clear the blockage. The study aims to see if this treatment can speed up recovery and help children recover faster. Gastrografin has been used in various studies to accelerate the resolution of intestinal blockages and help children recover faster.

Eligible Conditions

Small Bowel Obstruction

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

rate of surgical intervention

Secondary study objectives

Length of hospital stay

Rate of complications

Time to first feed

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Gastrografin ArmExperimental Treatment1 Intervention

Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.

Group II: Control ArmExperimental Treatment1 Intervention

Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.

Do I qualify?Apply below to find out